KWM
RVNC

Kingsview Wealth Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Kingsview Wealth Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,982
Closed -$289K – 989
2023
Q1 		$289K Buy
+8,982
New +$280K 0.01% 714
2022
Q4 		– Sell
-8,982
Closed -$243K – 913
2022
Q3 		$243K Buy
+8,982
New +$182K 0.01% 700

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kingsview Wealth Management's RVNC Position: Q2 2023 in Review

Kingsview Wealth Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 8,982 shares — an estimated $289K sold.

Kingsview Wealth Management first reported a position in RVNC in Q3 2022 and held it in 2 quarters. The position peaked at $289K in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • Kingsview Wealth Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Kingsview Wealth Management sold 8,982 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $289K.
  • Kingsview Wealth Management first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 2 quarters.
  • Kingsview Wealth Management's Revance Therapeutics, Inc. position peaked at $289K in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Kingsview Wealth Management's 13F filing for Q2 2023, filed 10 Aug 2023.